Visiongain has released its new Antibody Drug Conjugates Market Report 2026-2036, forecasting that the global market will grow from US$18.42 billion in 2026 to US$55.94 billion by 2036.

The market is forecast to expand at a compound annual growth rate (CAGR) of 11.8% between 2026 and 2036, driven by the rising global cancer burden, accelerating R&D investment in next-generation ADC platforms, novel target diversification beyond HER2, and expanding clinical adoption of ADC combination therapies.

Key Market Growth Drivers & Industry Transformations

The global ADC market is entering a new phase of growth as developers move beyond established targets, extend ADC use into new indications and disease areas, and advance next-generation conjugation, linker, and payload technologies. Visiongain’s research identifies four key catalysts driving market expansion:

• Rising Global Cancer Burden Strengthening Demand: WHO’s 2026 cancer statistics identify lung, breast, colorectal, and prostate cancers among the most commonly diagnosed malignancies worldwide, with approximately 2.6 million new lung cancer cases, 2.4 million breast cancer cases, and 2.0 million colorectal cases annually. The American Cancer Society estimates 2,114,850 new cancer cases and 626,140 cancer deaths in the US in 2026 alone. This substantial and diversifying cancer burden is increasing demand for targeted systemic therapies, particularly for advanced, metastatic, and treatment-resistant disease where ADCs offer precision delivery.
• Novel Target Diversification Fuelling Pipeline Expansion: Pipeline activity is expanding beyond established targets such as HER2 to include HER3, B7-H3, B7-H4, CLDN18.2, ROR1, ITGB6, CEACAM, and CDH6, with B7-H3 and CLDN18.2 attracting particularly strong development interest. Bispecific ADCs targeting combinations such as EGFR/HER3 and CD3/CD7 are also advancing. Developers are simultaneously extending established targets into additional indications, including Nectin-4 ADCs for cervical cancer and HER2-directed candidates for ovarian and endometrial cancers.
• Accelerating R&D Investment Expanding the Next-Generation Pipeline: Capital continues to flow into specialist ADC developers: Sidewinder Therapeutics raised US$137 million in Series B financing in April 2026, Adcendo raised US$75 million in an oversubscribed Series C in April 2026, and Solve Therapeutics raised US$120 million in November 2025. According to Seoul Economic Daily, Chinese assets made up approximately US$11 billion, or 91%, of the US$12.1 billion in disclosed ADC licensing value in the first half of 2026, underscoring the global scale of ADC investment.
• ADC Combination Therapies Broadening Clinical Applications: On 10 July 2026, the FDA approved Padcev (enfortumab vedotin) in combination with Keytruda (pembrolizumab) as neoadjuvant treatment for certain patients with muscle-invasive bladder cancer, expanding the ADC-immunotherapy combination into earlier-stage disease. Combinations with checkpoint inhibitors, chemotherapy, and targeted therapies are increasingly being evaluated to address resistance, tumour heterogeneity, and insufficient selectivity in monotherapy settings.

What This Means for the ADC Market

The ADC market is transitioning from a relatively concentrated, HER2-centred commercial landscape into a broad multi-target, multi-indication market with significant expansion into solid tumours, haematological malignancies, and emerging non-oncology applications. Trade tariffs and U.S. biosecurity policy measures are reshaping sourcing, manufacturing, and partnership strategies rather than reducing demand – companies are responding by diversifying supply chains, qualifying alternative CDMOs, and expanding regional manufacturing. The commercial importance of Chinese ADC innovation means companies must simultaneously balance supply-chain risk against continued access to a significant source of new ADC technologies and pipeline assets.

Download Sample Request

Executive Quote

“The ADC market is evolving rapidly from a concentrated set of established products toward a broad, multi-target, multi-indication landscape where next-generation platform innovation and combination strategies are reshaping competitive dynamics,” stated a Senior Pharma Analyst at Visiongain.

“Over the next decade, companies that combine novel target selection, advanced conjugation technologies, and diversified manufacturing strategies will be best positioned to capture value as the market continues to expand well beyond its current commercial base.”

Scope of the Visiongain Report

The 415+ page report provides robust quantitative and qualitative analysis across all key facets of the global market:

• By Product: Kadcyla; Enhertu; Adcetris; Padcev; Trodelvy; Polivy; Others (Elahere, Tivdak, Zynlonta, Blenrep, Mylotarg).
• By Payload Type: Auristatins; Maytansinoids; Calicheamicin Derivatives; Topoisomerase I Inhibitors; Pyrrolobenzodiazepine (PBD) Dimers; Other Payload Type.
• By Linker Type: Cleavable Linkers; Non-Cleavable Linkers.
• By Target Antigen: CD30; HER2; CD22; CD33; Other Target Antigens (TROP2, Nectin-4, FRa, HER-3, B7-H3).
• By Application: Blood Cancer; Breast Cancer; Autoimmune Diseases; Infectious Diseases; Other Applications (Lung, Gastric, Urothelial, Ovarian, Colorectal, Others).
• By End User: Hospitals & Clinics; Speciality Centres; Others (Academic Institutions, Research Organisations, Clinical Trial Centres).
• By Regional & Country Markets: North America, Europe, Asia Pacific, Latin America, and MEA.

Competitive Landscape

The competitive environment is characterised by large pharmaceutical companies defending established ADC franchises, specialist ADC developers advancing differentiated platforms, and a growing cohort of Chinese biotechnology companies providing both innovation assets and development services. Major market participants evaluated in the report include:

• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• Daiichi Sankyo Company, Limited
• AstraZeneca
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• ADC Therapeutics SA
• The Servier Laboratories
• BioNTech
• Novartis AG
• Johnson & Johnson
• BeOne Medicines
• Zymeworks Inc.
• Innovent
• Astellas Pharma Inc.
• AbbVie Inc.
• GSK plc
• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• Duality Biologics
• Merck & Co., Inc.

Recent Developments

• 31 Jul 2026 – AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) was approved in the EU as monotherapy for first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer not candidates for PD-1/PD-L1 inhibitor therapy.
• 29 Jul 2026 – AbbVie announced the availability of ELAHERE (mirvetuximab soravtansine) in Singapore for platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• 24 Jul 2026 – Gilead Sciences announced a positive CHMP opinion for Trodelvy (sacituzumab govitecan) in combination with Keytruda for adult patients with unresectable locally advanced or metastatic TNBC whose tumours express PD-L1 with CPS >=10.
• 10 Jul 2026 – FDA approved Padcev (enfortumab vedotin) in combination with Keytruda as neoadjuvant treatmentfor certain patients with muscle-invasive bladder cancer, followed by adjuvant therapy after cystectomy.

Download Sample Request

Related Reports

Active Pharmaceutical Ingredients (APIs) Market Report 2026-2036

Cell & Gene Therapy Manufacturing Market Report 2026-2036

mRNA Vaccines Market Report 2026-2036

About Visiongain

Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.

Media Contact

press@visiongain.com
+44 (0)20 7336 6100
www.visiongain.com